Literature DB >> 29800446

The Spectrum of Subclinical Primary Aldosteronism and Incident Hypertension.

Jenifer M Brown1, Anand Vaidya1.   

Abstract

Entities:  

Mesh：

Year:  2018        PMID： 29800446      PMCID： PMC7553731          DOI： 10.7326/L18-0027

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN： 0003-4819            Impact factor:   25.391


× No keyword cloud information.
  5 in total

Review 1.  Primary Aldosteronism: The Next Five Years.

Authors:  John W Funder
Journal:  Horm Metab Res       Date:  2017-10-24       Impact factor: 2.936

2.  Evidence of primary aldosteronism in a predominantly female cohort of normotensive individuals: a very high odds ratio for progression into arterial hypertension.

Authors:  Athina Markou; Theodora Pappa; Gregory Kaltsas; Aggeliki Gouli; Kostas Mitsakis; Panayiotis Tsounas; Anastasia Prevoli; Vaios Tsiavos; Labrini Papanastasiou; George Zografos; George P Chrousos; George P Piaditis
Journal:  J Clin Endocrinol Metab       Date:  2013-03-07       Impact factor: 5.958

3.  Serum aldosterone and the incidence of hypertension in nonhypertensive persons.

Authors:  Ramachandran S Vasan; Jane C Evans; Martin G Larson; Peter W F Wilson; James B Meigs; Nader Rifai; Emelia J Benjamin; Daniel Levy
Journal:  N Engl J Med       Date:  2004-07-01       Impact factor: 91.245

4.  Continuum of Renin-Independent Aldosteronism in Normotension.

Authors:  Rene Baudrand; Francisco J Guarda; Carlos Fardella; Gregory Hundemer; Jenifer Brown; Gordon Williams; Anand Vaidya
Journal:  Hypertension       Date:  2017-03-13       Impact factor: 10.190

Review 5.  The Low-Renin Hypertension Phenotype: Genetics and the Role of the Mineralocorticoid Receptor.

Authors:  Rene Baudrand; Anand Vaidya
Journal:  Int J Mol Sci       Date:  2018-02-11       Impact factor: 5.923
  5 in total
  1 in total

Review 1.  The Potential Role of Aldosterone-Producing Cell Clusters in Adrenal Disease.

Authors:  Jung Soo Lim; William E Rainey
Journal:  Horm Metab Res       Date:  2020-03-30       Impact factor: 2.936
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.